下肢血运重建术后血管闭合装置或手动压迫的入路部位并发症不常见
基于血管质量倡议(VQI)2010至2020年84,172例下肢外周血管介入(PVI)的倾向性评分匹配分析,比较手动压迫(MC)与四种血管闭合装置(VCD)的围手术期结局。任何VCD相比MC血肿发生率更低(1.7% vs 3.6%,P<.001),需干预的血肿也更少(0.2% vs 0.5%,P<.001);入路部位狭窄/闭塞两组相似(0.2% vs 0.2%,P=.12)。
要点
- 任何VCD相比MC血肿发生率更低(1.7% vs 3.6%,P<.001)。
- 需干预的血肿VCD组少于MC组(0.2% vs 0.5%,P<.001)。
- 入路部位狭窄/闭塞MC与任何VCD组相似(0.2% vs 0.2%,P=.12)。
核心结论
- 尽管无论止血技术如何需干预的血肿总体发生率均低,但任何类型VCD相比MC均更具优势,PVI术后入路部位并发症显著更少。
研究设计与样本
- 查询血管质量倡议(VQI)数据库,纳入2010至2020年所有经股总动脉入路的下肢PVI。
- 比较MC与四种VCD(MynxGrip、StarClose SE、Angio-Seal、Perclose ProGlide,盲法标记为A、B、C、D)的基线特征、手术细节和结局。
- 排除鞘管尺寸>8F者,进行1:1倾向性评分匹配,对未匹配和匹配数据行单变量和多变量分析。
- 共识别84,172例下肢PVI,其中MC 32,013例(38%),VCD 52,159例(62%)(A 12,675例;B 6,224例;C 19,872例;D 13,388例)。
- 平均年龄68.7岁,60.4%为男性;最常见干预指征为跛行(43.8%)和组织缺损(40.1%)。
主要发现
- 相比MC,VCD更常用于肥胖、糖尿病和终末期肾病患者(P<.001 for all)。
- VCD较少用于高血压、慢性阻塞性肺疾病、冠心病、既往经皮冠脉和肢体干预及大截肢患者(P<.001 for all)。
- VCD在股腘(73% vs 63.8%)和胫(33.8% vs 22.3%)干预中较MC更常用,但在髂干预中较少用(20.6% vs 34.7%;P<.001 for all)。
- 鱼精蛋白在VCD组使用较少(19.1% vs 25.6%;P<.001)。
- 总体发生2,003例血肿(2.4%),其中278例(13.9%)需凝血酶或手术干预。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Vascular closure devices (VCDs) and manual compression (MC) are used to achieve hemostasis after peripheral vascular interventions (PVIs). We sought to compare perioperative outcomes between MC and four VCDs after PVI in a multicenter setting. METHODS: The Vascular Quality Initiative was queried for all lower extremity PVIs with common femoral artery access performed from 2010 to 2020. The VCDs included were MynxGrip (Cordis, Santa Clara, CA), StarClose SE (Abbott Vascular, Redwood City, CA), Angio-Seal (Terumo, Somerset, NJ), and Perclose ProGlide (Abbott Vascular). In a blinded fashion, these four VCDs (labeled A, B, C, and D) were compared to MC for baseline characteristics, procedural details, and outcomes (access site hematoma and stenosis/occlusion). Those with a sheath size >8F were excluded. Propensity score matching (1:1) was performed. Univariable and multivariable analyses were completed for unmatched and matched data. RESULTS: A total of 84,172 lower extremity PVIs were identified. Of these, 32,013 (38%) had used MC and 52,159 (62%) had used VCDs (A, 12,675; B, 6224; C, 19,872; D, 13,388). The average age was 68.7 years, and 60.4% of the patients were men. The most common indications for intervention were claudication (43.8%) and tissue loss (40.1%). Compared with MC, VCDs were used more often for patients with obesity, diabetes, and end-stage renal disease (P < .001 for all). VCDs were used less often for patients with hypertension, chronic obstructive pulmonary disease, coronary artery disease, prior percutaneous coronary and extremity interventions, and major amputation (P < .001 for all). VCD use was more common than MC during femoropopliteal (73% vs 63.8%) and tibial (33.8% vs 22.3%) interventions but less common with iliac interventions (20.6% vs 34.7%; P < .001 for all). Protamine was used less often with VCDs (19.1% vs 25.6%; P < .001). Overall, 2003 hematomas had developed (2.4%), of which 278 (13.9%) had required thrombin or surgical intervention. Compared with MC, the use of any VCD had resulted in fewer hematomas (1.7% vs 3.6%; P < .001) and fewer hematomas requiring intervention (0.2% vs 0.5%; P < .001). When divided by hemostatic technique, the rate of the development of any hematoma was as follows: MC, 3.6%; VCD A, 1.4%; VCD B, 1.2%; VCD C, 2.3%; and VCD D, 1.1% (P < .001). The rate of hematomas requiring intervention was as follows: MC, 0.5%; VCD A, 0.2%; VCD B, 0.2%; VCD C, 0.3%; and VCD D, 0.1% (P < .001). Access site stenosis/occlusion was similar between the MC and any VCD groups (0.2% vs 0.2%; P = .12). Multivariable analysis demonstrated that any VCD use and the use of the individual VCDs compared with MC were independently associated with the development of fewer hematomas. The incidence of access site stenosis/occlusion was similar between the use of any VCD and MC. The matched analysis revealed similar findings. CONCLUSIONS: Although the overall rates of hematomas requiring intervention were low regardless of hemostatic technique, VCD use, irrespective of type, compared favorably with MC, with significantly fewer access site complications after PVI.
引用
- Cheng TW, Farber A, King EG, et al. Access site complications are uncommon with vascular closure devices or manual compression after lower extremity revascularization. J Vasc Surg. 2022. PMID: 35618194. doi:10.1016/j.jvs.2022.03.890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。